Overexpression of KMT2A is associated with worse prognosis and specific immune signatures in patients with TP53-mutated hepatocellular carcinomas


Liang Sha1, Jun Yin4, Sungming Kim2, Jian Zhang4, Alex Farrell4, Joanne Xiu4, David Spetzler4, Sam Wei5, Dave S Hoon6, Stephen Liu7, Emil Lou8, Misako Nagasaka9, Wafik El-Deiry10, Benedito Carneiro10, W. Michael Korn4, Heinz-Josef Lenz1, Woojin An3, Yali Dou1


Aberrant expression of epigenetic regulators is often associated with pathogenesis. Histone H3K4 methyltransferase, known as KMT2A, has been implicated in transcription and cell cycle regulation in pediatric leukemia and myeloma. However, the role of KMT2A expression in solid tumors is under-investigated. Here we examine the implications of KMT2A overexpression in prognosis, gene pathway enrichment, aneuploidy and immune infiltration patterns using a large, real-world clinical HCC dataset.

Download Publication